GlassScriptPhysician profile
Ronald P Kaufman
NPI 1487734430
$173,182.04
in general payments reported to CMS, 2019-2025
32 companies · $3,062 in 2025
The $3,062 reported for 2025 was more than what 87% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $47K · 2021: $5,179 · 2022: $30K · 2023: $23K · 2024: $8,780 · 2025: $3,062.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $24K · Food and Beverage: $3,491 · Travel and Lodging: $3,104 · Honoraria: $2,500 · Consulting Fee: $1,875 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $23,616.84 |
| Food and Beverage | $3,490.53 |
| Travel and Lodging | $3,104.35 |
| Honoraria | $2,500.00 |
| Consulting Fee | $1,875.00 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $57,350.88 | 2021-2025 | Urolift, Barrigel |
| Swan Valley Medical Incorporated | $42,340.06 | 2019-2020 | |
| Astellas Pharma US INC | $36,172.02 | 2019-2025 | Xtandi |
| Janssen Biotech, INC. | $11,342.50 | 2019-2025 | Erleada, Rybrevant, Carvykti |
| Janssen Pharmaceuticals, INC | $9,124.25 | 2019-2020 | |
| Neotract INC. | $8,399.26 | 2019-2020 | |
| Astellas Pharma Global Development | $1,912.55 | 2023-2025 | Xtandi |
| Intuitive Surgical, INC. | $1,593.32 | 2020-2024 | |
| Immunitybio, INC. | $1,500.00 | 2024 | |
| Provepharm INC. | $1,142.07 | 2023 | Bludigo |
| Progenics Pharmaceuticals, INC. | $252.80 | 2024 | |
| Boston Scientific Corporation | $242.32 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $216.74 | 2022 | |
| Procept Biorobotics Corporation | $204.09 | 2024-2025 | Aquabeam System |
| Novartis Pharmaceuticals Corporation | $176.61 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $162.35 | 2025 | Provenge |
| Sumitomo Pharma America, INC. | $141.26 | 2023-2024 | Orgovyx |
| Astellas Pharma INC | $140.88 | 2024 | Xtandi |
| Urogen Pharma, INC. | $139.45 | 2023-2024 | Jelmyto |
| Pfizer INC. | $135.94 | 2025 | |
| Merck Sharp & Dohme LLC | $124.88 | 2024 | Keytruda |
| Baxter Healthcare | $124.67 | 2021 | |
| Comsort, INC | $100.00 | 2019 | |
| Ferring Pharmaceuticals INC. | $89.14 | 2024-2025 | Adstiladrin |
| Alnylam Pharmaceuticals INC. | $23.02 | 2025 | Givlaari |
| Astrazeneca Pharmaceuticals LP | $16.23 | 2025 | Lynparza |
| Antares Pharma, INC. | $14.75 | 2025 | Xyosted |
5 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$0.05 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Kaufman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.